Steven T. Merrick
Chief Executive Officer
Mr. Merrick joined the St. Renatus team in September 2009. As the chief executive officer, he oversees all operations to help fund, complete the FDA process, commercialize, and distribute the new drug. Prior to joining St. Renatus, Mr. Merrick served for 15 years in various management positions for Septodont, the world’s leading provider of injectable dental anesthetics. He held the position of vice president of global marketing for The Pain Control Division during his last three years at Septodont. During his tenure, he was involved in the FDA approval process for a variety of local anesthetics including the best-selling branded anesthetic in dentistry, Septocaine.
Mr. Merrick received a B.A. in Marketing from Rider University in Lawrenceville, New Jersey in 1986. Throughout his professional years, Mr. Merrick has involved himself in many business associations, including serving as the Chairman of Exhibits Committee of The Dental Trade Alliance (DTA) from 2007 to 2009. He currently is a member of the American Dental Association (ADA) working with a group for dental anesthetics, needles, and syringes.
Jill M. Shoemaker, M.B.A.
Vice President of Investor Relations
Ms. Shoemaker helped launch the company in 2008. Prior to becoming vice president of investor relations, she served as the director of finance. Formerly, she was a financial advisor with Merrill Lynch. Ms. Shoemaker began her business career with Oak Associates, ltd., a privately held large capital growth investment manager. She has ten years of security and client relationship management experience. She serves on two community boards, Project Smile and Canyon Concert Ballet.
Ms. Shoemaker received a B.A. in fine arts from The College of Wooster and an M.B.A. from Malone College.
Paul G. Sletten, D.D.S.
Director of Scientific and Clinical Affairs
Dr. Sletten joined the St. Renatus team in March of 2009. As the Director of Scientific and Clinical Affairs, Dr. Sletten coordinates scientific and clinical projects related to the FDA Phase 3 clinical process with Mr. Merrick, Dr. Kollar, and the Scientific Advisory Board. Prior to joining St. Renatus, Dr. Sletten worked as a restorative dentist in the University of Minnesota Community Health Care System until moving into private practice, where he has worked and studied with groups on an international level.
Dr. Sletten received his B.A. in Biology and a minor in Chemistry and Business Administration from Concordia College in Moorhead, Minnesota. He then attended the University of Minnesota School of Dentistry and spent a quarter as a dental exchange student in Denmark. After graduating, Dr. Sletten continued with his residency at the University of Minnesota School of Dentistry in the Advanced Education of General Dentistry (AEGD) program.
Sandra Brown, Ph.D
Director of Technical Affairs
Dr. Brown joined St. Renatus, LLC in May 2010. As Director of Technical Affairs, Dr. Brown oversees manufacturing and regulatory issues surrounding the production and ongoing stability studies of the nasal mist product development. Dr. Brown has more than 25 years of experience as a consultant to pharmaceutical firms, preparing Investigational (IND) and New Drug (NDA) applications and assisting in readiness for undergoing FDA inspections of manufacturing facilities, with participation in obtaining approvals for more than 20 new drug products. Prior to becoming a consultant, Dr. Brown was a chemistry reviewer for new drugs at the FDA and worked in the chemical manufacturing industry.
Dr. Brown received a B.A. in Chemistry from George Washington University and went on to receive her Ph.D. in Physical Chemistry from the University of South Carolina.